Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance.

View Full Paper
Ask AI
Bookmark
Share

Authors

VVVamsidhar VelchetiXSXuezheng SunMHMaya Hanna

Discussion

Loading...

Member takes

Overview

Observational analysis reveals predictors of worse outcomes in advanced non-small cell lung cancer, highlighting weight loss and PD-L1 status.

Key Points

  • Median overall survival was 18.7 months, indicating significant survival time for patients receiving treatment.
  • Patients with ≥10% weight loss showed a worse hazard ratio of 1.69, revealing a strong link to negative outcomes.
  • Analysis of electronic health records provided insights into real-world treatment effects for advanced cancer patients.
  • Results underscore the need for improved strategies, as poor outcomes continue despite immunotherapy advancements.

Cite This Study

Velcheti et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64785060https://doi.org/10.1093/oncolo/oyaf070
View Full Paper
Ask AI
Bookmark
Share